# Effect of Tegoprazan or RAPA113 on Pharmacodynamics/Pharmacokinetics of Clopidogrel in Healthy Male Volunteers

> **NCT04171687** · PHASE1 · COMPLETED · sponsor: **HK inno.N Corporation** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Clopidogrel 75mg
- **DRUG:** Tegoprazan 50 mg
- **DRUG:** RAPA113

## Key facts

- **NCT ID:** NCT04171687
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-21
- **Primary completion:** 2020-02-07
- **Final completion:** 2020-04-09
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04171687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04171687, "Effect of Tegoprazan or RAPA113 on Pharmacodynamics/Pharmacokinetics of Clopidogrel in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04171687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*